Adagrasib Market Introdction: With a long half-life and a large volume of tissue distribution, adagrasib is a potent and selective inhibitor of KRAS G12C that maximizes the depth and duration of anti-tumor activity by continuously inhibiting KRAS-dependent signaling throughout the entire dose interval.Patients with a KRAS G12C mutation now have new hope thanks to the Adagrasib...